“Direct to Drug” screening as a precision medicine tool in multiple myeloma

Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin’s lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phenotype, cytogenetic, genetic mutation, and tran...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonolo de Campos, Cecilia, Meurice, Nathalie, Petit, Joachim L., Polito, Alysia N., Zhu, Yuan Xiao, Wang, Panwen, Bruins, Laura A., Wang, Xuewei, Lopez Armenta, Ilsel D., Darvish, Susie A., Ahmann, Greg J., Henderson, Kimberly J., Tian, Shulan, Kruse, Jonas J., Stewart, William M., Larsen, Jeremy T., Reeder, Craig B., Dingli, David, Kapoor, Prashant, Kumar, Shaji K., Fonseca, Rafael, Bergsagel, P. Leif, Braggio, Esteban, Stewart, A. Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214452/
https://www.ncbi.nlm.nih.gov/pubmed/32393731
http://dx.doi.org/10.1038/s41408-020-0320-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214452/
https://www.ncbi.nlm.nih.gov/pubmed/32393731
http://dx.doi.org/10.1038/s41408-020-0320-7

Ejemplares similares